ABVX:NASDAQ
Abivax SA
US$ ८९.०६
arrow_downward
-०.८७%(-०.७८) 1D
US$ ८७.४१
arrow_downward
-१.८५% (-१.६५)todayPre-market
Closed: अक्टोबर २९, १६:००:०१ GMT-४ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
US$ ८९.८५
High
US$ ९२.०९
Low
US$ ८८.३९
Mkt. cap
६.८६ अरब
Avg. vol.
१२.५१ लाख
Volume
५.९६ हजार
52-wk high
US$ १४८.८३
52-wk low
US$ ६९.८१
Shares outstanding
८.७५ करोड
No. of employees
९८
Open
US$ ८९.८५
High
US$ ९२.०९
Low
US$ ८८.३९
Mkt. cap
६.८६ अरब
Avg. vol.
१२.५१ लाख
Volume
५.९६ हजार
52-wk high
US$ १४८.८३
52-wk low
US$ ६९.८१
Shares outstanding
८.७५ करोड
No. of employees
९८
News stories
From web sources and news partners
CryptoSlate
·
३७ मिनेट पहिले
Walmart, Microsoft and JPMorgan block NYSE-backed venture from tokenizing their shares
Reuters
·
४९ मिनेट पहिले
Nasdaq futures tumble as Amazon, Intel results deepen AI spending woes
Bloomberg.com
·
१ घण्टा पहिले
Asia Stocks Under Pressure, Haven Bid Boosts Bonds: Markets Wrap
Barron's
·
१० घण्टा पहिले
ServiceNow Stock Is Worst in S&P 500 After a Key Revenue Measure Fell Short
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees९८
Founded२०१३ डिसेम्बर ४
Headquarters-
Sector-
Websiteabivax.com